Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for National Institute of Diabetes and Digestive and Kidney Diseases Consortia

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 7, 2010, Pages 3360-3367

  Bonifacio, Ezio ^a   Yu, Liping ^b   Williams, Alastair K ^c   Eisenbarth, George S ^b   Bingley, Polly J ^c   Marcovina, Santica M ^d   Adler, Kerstin ^e   Ziegler, Anette G ^e   Mueller, Patricia W ^f   Schatz, Desmond A ^g   Krischer, Jeffrey P ^h   Steffes, Michael W ⁱ   Akolkar, Beena ^j  

^a Deutsche Forschungsgemeinschaft   (Germany)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF WASHINGTON   (United States)

^e INSTITUT FÜR DIABETESFORSCHUNG   (Germany)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g UNIVERSITY OF FLORIDA   (United States)

^h UNIVERSITY OF SOUTH FLORIDA   (United States)

ⁱ UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^j NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; AUTOANTIBODY; GLUTAMATE DECARBOXYLASE; ISLET ANTIGEN 2 AUTOANTIBODY; METHIONINE S 35; SULFUR 35; UNCLASSIFIED DRUG; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE;

ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CALIBRATOR; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; HEALTH PROGRAM; HUMAN; IMMUNOASSAY; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; ISOTOPE LABELING; LABORATORY; LABORATORY TEST; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NATIONAL HEALTH ORGANIZATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SERUM; WORLD HEALTH ORGANIZATION; ADOLESCENT; ADULT; IMMUNOLOGY; METHODOLOGY; ORGANIZATION; RADIOASSAY; REFERENCE VALUE;

ACADEMIES AND INSTITUTES; ADOLESCENT; ADULT; AUTOANTIBODIES; GLUTAMATE DECARBOXYLASE; HUMANS; RADIOLIGAND ASSAY; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 8; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY;

EID: 77954949830     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0293     Document Type: Article

References (16)

1. American Diabetes Association 2008 Diagnosis and classification of diabetes mellitus. Diabetes Care 31:S55-S60
2. Törn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ; Participating Laboratories 2008 Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 51:846-852
3. Qu HQ, Polychronakos C 2009 The effect of the MHC locus on autoantibodies in type 1 diabetes. J Med Genet 46:469-471
4. TEDDY Study Group 2008 The Environmental Determinants of Diabetes in the Young (TEDDY) Study. Ann NY Acad Sci 1150:1-13
5. Skyler JS, Greenbaum CJ, Lachin JM, Leschek E, Rafkin-Mervis L, Savage P, Spain L; Type 1 Diabetes TrialNet Study Group 2008 Type 1 Diabetes TrialNet - an international collaborative clinical trials network. Ann NY Acad Sci 1150:14-24
6. The SEARCH Study Group 2004 SEARCH for Diabetes in Youth: a multicenter study of the prevalence, incidence and classification of diabetes mellitus in youth. Control Clin Trials 25:458-471
7. Zeitler P, Epstein L, Grey M, Hirst K, Kaufman F, Tamborlane W, Wilfley D 2007 Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes 8:74-87
8. Dabelea D, Kinney G, Snell-Bergeon JK, Hokanson JE, Eckel RH, Ehrlich J, Garg S, Hamman RF, Rewers M 2003 Coronary Artery Calcification in Type 1 Diabetes Study. Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Diabetes 52:2833-2839
9. Yu L, Rewers M, Gianani R, Kawasaki E, Zhang Y, Verge C, Chase P, Klingensmith G, Erlich H, Norris J, Eisenbarth GS 1996 Antiislet autoantibodies develop sequentially rather than simultaneously. J Clin Endocrinol Metab 81:4264-4267
10. Bingley PJ, Williams AJ, Gale EA 1999 Optimized autoantibody-based risk assessment in family members. Implications for future intervention trials. Diabetes Care 22:1796-1801
11. Ziegler AG, Hummel M, Schenker M, Bonifacio E 1999 Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48:460-468
12. Williams AJ, Somerville M, Rokni S, Bonifacio E, Yu L, Eisenbarth G, Akolkar B, Steffes M, Bingley PJ 2009 Azide and Tween-20 reduce binding to autoantibody epitopes of islet antigen-2; implications for assay performance and reproducibility. J Immunol Methods 351:75-79
13. Schmidli RS, Colman PG, Bonifacio E, Bottazzo GF, Harrison LC 1994 High level of concordance between assays for glutamic acid decarboxylase antibodies. The First International Glutamic Acid Decarboxylase Antibody Workshop. Diabetes 43:1005-1009
14. Bingley PJ, Bonifacio E, Mueller PW 2003 Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 52:1128-1136
15. Mire-Sluis AR, Gaines Das R, Lernmark A 2000 The World Health Organization International Collaborative Study for islet cell antibodies. Diabetologia 43:1282-1292
16. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, Rewers M, Eisenbarth GS, Jensen J, Davidson HW, Hutton JC 2007 The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 104:17040-17045